// App-Quantinova.ai

P1-19-09 : Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)

Researchers

Presenter

  • Joyce OShaughnessy

Principal Investigators

  • Stephen Johnston

  • Miguel Martin

  • Jens Huober

  • Masakazu Toi

  • Valerie AnneMarie Andre

  • Holly Rene Martin

  • Molly Catherine Hardebeck

  • Angelo Di Leo

  • Matthew Philip Goetz

Medical Centers

  • Texas Oncology/Baylor Sammons Cancer Center/US Oncology, Dallas, TX

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Instituto de Investigacion Sanitaria Gregorio Maranon, Universidad Complutense, Madrid, Spain

  • Comprehensive Cancer Center Ulm, Ulm University Hospital, Ulm, Germany

  • Department of Surgery, Kyoto University, Kyoto, Japan

  • Eli Lilly and Company, Paris, France

  • Eli Lilly and Company, Indianapolis, IN

  • Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

  • Department of Oncology, Mayo Clinic, Rochester, MN

Locations

  • United States

  • United Kingdom

  • Spain

  • Germany

  • Japan

  • France

  • Italy

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

  • Transthyretin

Drug/Treatment

  • Abemaciclib

  • Anastrozole

  • Letrozole

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02246621

Sponsors

  • Eli Lilly

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved